Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shanghai - Delayed Quote CNY

TIANTAN BIO (600161.SS)

Compare
22.02
+1.33
+(6.43%)
At close: 3:00:03 PM GMT+8
Loading Chart for 600161.SS
  • Previous Close 20.69
  • Open 21.80
  • Bid 22.01 x --
  • Ask 22.02 x --
  • Day's Range 21.25 - 22.75
  • 52 Week Range 18.88 - 27.60
  • Volume 138,943,822
  • Avg. Volume 12,603,952
  • Market Cap (intraday) 43.542B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 28.23
  • EPS (TTM) 0.78
  • Earnings Date Apr 26, 2025
  • Forward Dividend & Yield 0.15 (0.72%)
  • Ex-Dividend Date Jun 20, 2024
  • 1y Target Est --

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. Beijing Tiantan Biological Products Co., Ltd. was founded in 1966 and is headquartered in Beijing, China.

www.tiantanbio.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 600161.SS

View More

Performance Overview: 600161.SS

Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600161.SS
7.41%
SSE Composite Index (000001.SS)
7.61%

1-Year Return

600161.SS
1.58%
SSE Composite Index (000001.SS)
0.89%

3-Year Return

600161.SS
38.32%
SSE Composite Index (000001.SS)
4.33%

5-Year Return

600161.SS
6.12%
SSE Composite Index (000001.SS)
9.78%

Compare To: 600161.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 600161.SS

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    40.91B

  • Enterprise Value

    38.28B

  • Trailing P/E

    26.53

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.81

  • Price/Book (mrq)

    3.67

  • Enterprise Value/Revenue

    6.35

  • Enterprise Value/EBITDA

    13.27

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    25.68%

  • Return on Assets (ttm)

    10.48%

  • Return on Equity (ttm)

    15.48%

  • Revenue (ttm)

    6.03B

  • Net Income Avi to Common (ttm)

    1.55B

  • Diluted EPS (ttm)

    0.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.69B

  • Total Debt/Equity (mrq)

    0.37%

  • Levered Free Cash Flow (ttm)

    -1.3B

Research Analysis: 600161.SS

View More

Company Insights: 600161.SS

Research Reports: 600161.SS

View More

People Also Watch